Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2025-11-05 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for Vicore Pharma Holding AB covering the period from July 1 to September 30, 2025. It contains detailed financial statements, management commentary (CEO comments), pipeline updates, and financial analysis. It is clearly a comprehensive quarterly financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). Q3 2025
2025-11-05 English
Vicore announces the Nomination Committee for the 2026 Annual General Meeting
Board/Management Information Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding the appointment of a Nomination Committee for an upcoming Annual General Meeting. It does not contain the actual AGM materials or proxy statements, but rather serves as a corporate announcement regarding the preparation for the meeting. As it does not fit into specific categories like 'Proxy Solicitation' (which is for voting materials) or 'AGM-R' (which is for meeting presentations), and it is a regulatory announcement regarding corporate governance preparation, it is best classified as a general regulatory filing.
2025-11-03 English
Vicore offentliggör valberedningen inför årsstämman 2026
Board/Management Information Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding the appointment of a nomination committee (valberedning) for an upcoming Annual General Meeting. It provides contact information and details on how shareholders can submit proposals, but it is not the meeting materials themselves. According to the 'Menu vs Meal' rule, this is a regulatory announcement regarding corporate governance preparations, which fits best under the 'Regulatory Filings' (RNS) category as it is a standard corporate disclosure.
2025-11-03 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB covering the period 1 April to 30 June 2025. It contains comprehensive financial statements, management commentary (VD-ord), notes, and key performance indicators. It is not an announcement of a report, but the report itself, containing substantive financial data. Q2 2025
2025-08-22 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for Vicore Pharma Holding AB covering the period from April 1 to June 30, 2025 (Q2). It contains comprehensive financial statements, management commentary, and performance metrics. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). Q2 2025
2025-08-22 English
Increase in number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces an 'Increase in number of shares and votes in Vicore Pharma' due to the exercise of warrants and incentive programs. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a short announcement, the core content is the capital change itself, not just an announcement of a report, making SHA a better fit than RPA or RNS. The document details the exact increase in shares (30,652) and the new total outstanding shares and share capital.
2025-06-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.